Evidence map›Paper›PMID 28634574›Full record

SynthesisFrontiers in cellular and infection microbiology2017

Reducing Viability Bias in Analysis of Gut Microbiota in Preterm Infants at Risk of NEC and Sepsis.

Gregory R Young, Darren L Smith, Nicholas D Embleton, Janet E Berrington, Edward C Schwalbe, Stephen P Cummings, Christopher J van der Gast, Clare Lanyon

Open access · goldAbstract readMeta-Analysis
In one paragraph

Synthesis in Frontiers in cellular and infection microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Observational
  4. Article
  5. Article
  6. mSystems · 2023
    Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Methods for exploring the faecal microbiome of premature infants: a review.Maternal health, neonatology and perinatology · 2021
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Gregory R YoungFaculty of Health and Life Sciences, University of NorthumbriaNewcastle upon Tyne, United Kingdom.
Darren L SmithFaculty of Health and Life Sciences, University of NorthumbriaNewcastle upon Tyne, United Kingdom.
Nicholas D EmbletonNewcastle Neonatal Service, Newcastle upon Tyne Hospitals NHS Foundation TrustNewcastle upon Tyne, United Kingdom.
Janet E BerringtonNewcastle Neonatal Service, Newcastle upon Tyne Hospitals NHS Foundation TrustNewcastle upon Tyne, United Kingdom.
Edward C SchwalbeFaculty of Health and Life Sciences, University of NorthumbriaNewcastle upon Tyne, United Kingdom.
Stephen P CummingsSchool of Science and Engineering, Teesside UniversityMiddlesbrough, United Kingdom.
Christopher J van der GastSchool of Healthcare Science, Manchester Metropolitan UniversityManchester, United Kingdom.
Clare LanyonFaculty of Health and Life Sciences, University of NorthumbriaNewcastle upon Tyne, United Kingdom.
Northumbria University · GBNewcastle upon Tyne Hospitals NHS Foundation Trust · GBManchester Metropolitan University · GBTeesside University · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Necrotising enterocolitis (NEC) and sepsis are serious diseases of preterm infants that can result in feeding intolerance, the need for bowel resection, impaired physiological and neurological development, and high mortality rates. Neonatal healthcare improvements have allowed greater survival rates in preterm infants leading to increased numbers at risk of developing NEC and sepsis. Gut bacteria play a role in protection from or propensity to these conditions and have therefore, been studied extensively using targeted 16S rRNA gene sequencing methods. However, exact epidemiology of these conditions remain unknown and the role of the gut microbiota in NEC remains enigmatic. Many studies have confounding variables such as differing clinical intervention strategies or major methodological issues such as the inability of 16S rRNA gene sequencing methods to determine viable from non-viable taxa. Identification of viable community members is important to identify links between the microbiota and disease in the highly unstable preterm infant gut. This is especially important as remnant DNA is robust and persists in the sampling environment following cell death. Chelation of such DNA prevents downstream amplification and inclusion in microbiota characterisation. This study validates use of propidium monoazide (PMA), a DNA chelating agent that is excluded by an undamaged bacterial membrane, to reduce bias associated with 16S rRNA gene analysis of clinical stool samples. We aim to improve identification of the viable microbiota in order to increase the accuracy of clinical inferences made regarding the impact of the preterm gut microbiota on health and disease. Gut microbiota analysis was completed on stools from matched twins (

Indexed as

Gastrointestinal MicrobiomeAzidesBacteriaBiasBiodiversityDNA, BacterialEnterocolitis, NecrotizingFecesGastrointestinal TractHumansInfantInfant, PrematurePolymerase Chain ReactionProbioticsPropidiumRNA, Ribosomal, 16SAzidesDNA, BacterialPropidiumpropidium monoazideRNA, Ribosomal, 16Smicrobiotaneonatepretermpropidium monoazidestoolviability

Identifiers

PMID28634574
PMCPMC5459914
OpenAlexW2623350814

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.